Title:
PHARMACEUTICAL COMPOSITION COMPRISING LIPOCALIN 2 INHIBITOR FOR PREVENTING OR TREATING LIVER FIBROSIS
Document Type and Number:
WIPO Patent Application WO/2024/090800
Kind Code:
A1
Abstract:
A lipocalin 2 Inhibitor of the present invention can exhibit the effects of preventing and treating liver fibrosis by inhibiting the induction of liver cells into hepatic stellate cells through the inhibition of lipocalin 2 expression, and thus a pharmaceutical composition comprising same is expected to be used in therapeutic agents and the like for exhibiting excellent treatment effects on liver fibrosis.
More Like This:
Inventors:
IM SEUNG SOON (KR)
LEE EUN HO (KR)
LEE EUN HO (KR)
Application Number:
PCT/KR2023/014274
Publication Date:
May 02, 2024
Filing Date:
September 20, 2023
Export Citation:
Assignee:
UNIV KEIMYUNG IACF (KR)
International Classes:
A61K48/00; A23L33/13; A61K31/7088; A61P1/16; A61P43/00
Foreign References:
| KR20150040185A | 2015-04-14 | |||
| KR20230112257A | 2023-07-27 |
Other References:
IM, SEUNG SOON: "Developmental mechanism and control strategy on nonalcoholic steaohapatitis by SREBP-1-mediated LCN2", MID-CAREER RESEARCH FINAL REPORT OF GOVERNMENT PROJECT, March 2022 (2022-03-01), pages 1 - 35
ANONYMOUS: "Identification of the mechanism controlling ‘fibrosis of non-alcoholic steatohepatitis’ caused by obesity and diabetes", GNU TODAY PRESS RELEASE, 17 May 2022 (2022-05-17), XP093163272, Retrieved from the Internet
CHEN JIEGEN, ARGEMI JOSEPMARIA, ODENA GEMMA, XU MING-JIANG, CAI YAN, MASSEY VERONICA, PARRISH AUSTIN, VADIGEPALLI RAJANIKANTH, ALT: "Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), XP055874089, DOI: 10.1038/s41598-020-72172-7
ANASTASIA ASIMAKOPOULOU: "Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy", FRONTIERS IN PHYSIOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 7, 27 September 2016 (2016-09-27), CH , XP093163276, ISSN: 1664-042X, DOI: 10.3389/fphys.2016.00430
KRIZANAC MARINELA, MASS SANCHEZ PAOLA BERENICE, WEISKIRCHEN RALF, ASIMAKOPOULOS ANASTASIA: "A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 6, pages 2865, XP093079155, DOI: 10.3390/ijms22062865
XU GANG, WANG YU-MIN, YING MIAO-MIAO, CHEN SUI-DAN, LI ZONG-RUI, MA HONG-LEI, ZHENG MING-HUA, WU JIAN, DING CHUNMING: "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", CLINICAL AND MOLECULAR HEPATOLOGY, KOREAN ASSOCIATION FOR THE STUDY OF THE LIVER, KOREA, vol. 27, no. 2, 1 April 2021 (2021-04-01), Korea , pages 329 - 345, XP093079156, ISSN: 2287-2728, DOI: 10.3350/cmh.2020.0261
KIM KYUNG EUN, LEE JAEWOONG, SHIN HYUN JOO, JEONG EUN AE, JANG HYE MIN, AHN YU JEONG, AN HYEONG SEOK, LEE JONG YOUL, SHIN MEONG CH: "Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 77, no. 3, 1 March 2023 (2023-03-01), US , pages 888 - 901, XP093079160, ISSN: 0270-9139, DOI: 10.1002/hep.32569
ANONYMOUS: "Identification of the mechanism controlling ‘fibrosis of non-alcoholic steatohepatitis’ caused by obesity and diabetes", GNU TODAY PRESS RELEASE, 17 May 2022 (2022-05-17), XP093163272, Retrieved from the Internet
CHEN JIEGEN, ARGEMI JOSEPMARIA, ODENA GEMMA, XU MING-JIANG, CAI YAN, MASSEY VERONICA, PARRISH AUSTIN, VADIGEPALLI RAJANIKANTH, ALT: "Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), XP055874089, DOI: 10.1038/s41598-020-72172-7
ANASTASIA ASIMAKOPOULOU: "Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy", FRONTIERS IN PHYSIOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 7, 27 September 2016 (2016-09-27), CH , XP093163276, ISSN: 1664-042X, DOI: 10.3389/fphys.2016.00430
KRIZANAC MARINELA, MASS SANCHEZ PAOLA BERENICE, WEISKIRCHEN RALF, ASIMAKOPOULOS ANASTASIA: "A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 6, pages 2865, XP093079155, DOI: 10.3390/ijms22062865
XU GANG, WANG YU-MIN, YING MIAO-MIAO, CHEN SUI-DAN, LI ZONG-RUI, MA HONG-LEI, ZHENG MING-HUA, WU JIAN, DING CHUNMING: "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", CLINICAL AND MOLECULAR HEPATOLOGY, KOREAN ASSOCIATION FOR THE STUDY OF THE LIVER, KOREA, vol. 27, no. 2, 1 April 2021 (2021-04-01), Korea , pages 329 - 345, XP093079156, ISSN: 2287-2728, DOI: 10.3350/cmh.2020.0261
KIM KYUNG EUN, LEE JAEWOONG, SHIN HYUN JOO, JEONG EUN AE, JANG HYE MIN, AHN YU JEONG, AN HYEONG SEOK, LEE JONG YOUL, SHIN MEONG CH: "Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 77, no. 3, 1 March 2023 (2023-03-01), US , pages 888 - 901, XP093079160, ISSN: 0270-9139, DOI: 10.1002/hep.32569
Attorney, Agent or Firm:
ISIS IP LAW LLC (KR)
Download PDF: